- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Business Brief
IBA teams with maker of novel PET agent
IBA teams with maker of novel PET agent
Ion Beam Applications and NeuroSurvival Technologies will work together to distribute, as well as optimize the radiochemistry of, NST's molecular imaging agent for apoptosis, the genetically controlled process of cell death associated with many diseases, including cancer. The agent, Aposense, will be distributed to sites participating in multicenter clinical trials to document whether the PET radiotracer incorporating fluorine-18 selectively targets and accumulates within cells undergoing apoptosis. IBA Molecular, a business unit of IBA, provides PET radiopharmaceuticals through a global network of radiopharmacies using 37 cyclotron-equipped manufacturing sites.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
